Search Results

Business

Endeavor BioMedicines Appoints Paul Frohna, M.D., Ph.D., as Chief Medical Officer

Endeavor BioMedicines, a clinical-stage company developing therapies for of fibrotic disease and oncology, announced the appointment of Paul Frohna, M.D., Ph.D., as its Chief Medical Officer.

November 2, 2023

·

3 min read

Drug Development

Bird Rock Bio Completes Clinical Trial of Nimacimab in Patients with Fatty Liver Disease

Nimacimab, also known as RYI-018 or JNJ-2463, is a negative-allosteric modulating antibody targeting the cannabinoid 1 recepto

September 13, 2018

·

3 min read

Business

TP Therapeutics Appoints Sheila K. Gujrathi, MD to Board of Directors and as a Strategic Advisor

Dr. Gujrathi most recently served as Chief Medical Officer of Receptos.

December 4, 2017

·

4 min read

Business

Two Former Receptos Execs Launch New San Diego Biotech Startup With $100M

It is not clear what the new company’s focus is just yet.

January 4, 2018

·

2 min read

·

Mark Terry

Deals

Celgene Commences Tender Offer For Receptos

July 28, 2015

·

5 min read

Business

Bioniz Therapeutics Appoints Graham Cooper to its Board of Directors

Most recently, Mr. Cooper was the CFO of Receptos from 2013 until its sale in 2015 to Celgene for $7.8B.

December 6, 2017

·

2 min read

Business

Vital Therapies Appoints Former Receptos President And CEO Faheem Hasnain As Chairman Of The Board Of Directors

September 6, 2017

·

4 min read

BioCapital

Remedy Plan Therapeutics Expands Leadership Team and Board of Directors

Remedy Plan Therapeutics, a small molecule therapeutics start-up company transforming the field of NAMPT inhibition, is pleased to announce the expansion of its leadership team with the appointment of Cassandra Choe-Juliak, M.D., M.S., as the acting Chief Medical Officer.

December 6, 2023

·

3 min read

$710M Gamble Fails as Celgene Terminates Two Phase

Drug Development

Celgene Admits It Screwed Up on Multiple Sclerosis Drug Application … Sort Of

This year the FDA issued a Refusal to File letter regarding its New Drug Application (NDA) for its multiple sclerosis drug ozanimod. The finger is pointed at its California subsidiary, Receptos for the failure.

June 13, 2018

·

2 min read

·

Mark Terry

Biotech Beach

Receptos To Present At UBS Global Healthcare Conference

May 14, 2015

·

1 min read